←
Phillip Scheinberg987 posts
Phillip Scheinberg avatar

Phillip Scheinberg

@scheinbp

Hematologist, Research Investigator, #BMFSM, #AplasticAnemia, #Telomeres, #MDS, #PNH, #LGL, #clinicalresearch Former fellow and staff @NIH_NHLBI

◷ Joined October 2012▧ 253 Photos and videos
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·26 Nov 2024

I am honored to become Editor-in-Chief of eJHaem, the Gold Open Access journal of the British Society for Haematology (BSH). After serving as Associate Editor of the British Journal of Haematology, I look forward to strengthening ties between these journals and advancing hematology research. As the first Latin American in this role, I am committed to making eJHaem a hub for innovation and collaboration. Thank you all for your support. b-s-h.org.uk/about-us/news/w… #BJH #EJH #BSH #EditorInChief

Post attachment
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·Jun 18

What is currently under construction will soon be another advancement in cell therapy at BP – Beneficência Portuguesa de São Paulo. Since 2016, when we inaugurated the unit at Hospital BP Mirante with 7 beds, we have been consistently building one of the most relevant programs in the country. In 2019, we carried out the first expansion at Hospital BP, with the addition of 10 new beds. In 2021, we took another leap forward, with 16 more beds dedicated to hematology and cell therapy. This growth reflects the work of a highly specialized and committed team — and translates into real impact: 📊 200 cell therapies performed in 2024, including bone marrow transplants and CAR-T therapy 📊 237 cell therapies in 2025, including bone marrow transplants and CAR-T therapy 📊 More than 1,500 transplants since 2016, in adult and pediatric patients For the seventh consecutive year, we are the center that performs the most transplants in Greater São Paulo — and we are among those that perform the most transplants in Brazil and Latin America. Today, BP is consolidating itself as one of the main cell therapy centers in the country and the region. The images show the behind-the-scenes of another expansion that will be delivered in May — an important step to expand capacity, innovation and access to highly complex therapies. More than physical growth, it is the continuation of a project built with purpose, excellence and a vision for the future. We continue to build. Literally. #CellTherapy #BoneMarrowTransplant #BMT #Hematology #LeadershipInHealth #HighComplexityMedicine #MedicalExcellence #BPMirante

Post attachmentPost attachmentPost attachmentPost attachment
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·24 Nov 2025

This November, I selected as Editor’s Choice for eJHaem the article “Real-World Management of Cytopenias and Infections in Patients with Myelofibrosis Treated with Ruxolitinib.” A practical, case-based review addressing everyday challenges in MF care: cytopenias, infections, and treatment optimization. eJHaem, the open-access journal of the British Society for Haematology published with Wiley, remains committed to delivering accessible, high-quality science. Watch the video! #eJHaem #Hematology #Myelofibrosis #MPN #EditorsChoice #ClinicalResearch #CaseBasedLearning #EvidenceBasedMedicine

7:32
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·18 Jun 2025

Big news: eJHaem has received its first-ever Impact Factor — 1.3! Launched in 2020, eJHaem, the open access journal of the British Society for Haematology (BSH), continues to grow in quality, reach, and scientific relevance. A heartfelt thank you to all readers, authors, reviewers, past and current associate editors, the editorial board, the British Journal of Haematology, the BSH, Wiley, and the broader hematoloy community who made this important milestone possible.

Post attachment
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·24 Feb 2025

Great news for Brazilian science! The Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES) has partnered with Wiley, providing access to nearly 2,000 scientific journals and enabling open-access publishing across Wiley’s hybrid journal portfolio for researchers from 434 Brazilian institutions. This partnership benefits six million researchers and students using the CAPES Portal, enhancing access to quality resources and boosting Brazilian research visibility globally. More access, more publications, and greater global impact for Brazilian research! 🔬📚✨ newsroom.wiley.com/press-rel…

Post attachment
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·25 Nov 2024

I am deeply honored and excited to announce my appointment as the new Editor-in-Chief of eJHaem, the Gold Open Access journal of the British Society for Haematology. Since its inception in 2020, eJHaem has steadily advanced its mission of promoting hematology knowledge across the globe. As this year comes to a close, I will complete my tenure with the British Journal of Haematology (BJH), where I have had the privilege of serving as Associate Editor since 2019. It has been a remarkable journey, and I am grateful for the opportunity to contribute to such a prestigious publication. I look forward to collaborating closely with Dr. Andrew Evens, the incoming Editor-in-Chief of BJH, as we work to strengthen the bond between these two distinguished journals and further elevate the global exchange of hematology research and innovation. It is a profound honor to be the first Editor-in-Chief from Latin America to lead a journal of the British Society for Haematology. I embrace this responsibility with great pride and a deep sense of duty, committed to enhancing eJHaem as a vibrant platform that inspires, connects, and drives innovation within the global hematology community. To everyone who has supported me along this journey—thank you. Together, let us continue to shape the future of hematology. b-s-h.org.uk/about-us/news/w… #EditorInChief #AssociateEditor #eJHaem #BritishJournalofHaematology #Hematology

Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·11 Nov 2024

O Summit CAR-T Cell é amanhã! Neste evento especial, o foco será na inovação que está revolucionando o tratamento de doenças autoimunes graves e refratárias. Contaremos com a presença do Dr. Fabian Mueller, da Universidade de Erlangen, que trará insights sobre a terapia "CD19 CAR T-Cell" e seu impacto em doenças complexas como lúpus e esclerodermia. Também teremos o Dr. Diego Villa Clé, do Hemocentro de Ribeirão Preto, para enriquecer essa discussão sobre o futuro das terapias avançadas. Estou animado para mediar este encontro transformador. Depois, compartilharei os detalhes de como foi a conversa do especialista com os médicos brasileiros. Fique ligado! 📅 Data: 12 de novembro ⏰ Horário: 13h00 às 14h30 📍 Local: Auditório BP Mirante O encontro é gratuito e não é preciso fazer inscrição. Não perca! #Hematologia #Hematologista #BP #OncoHematologia #ABeneficênciaPortuguesaDeSãoPaulo #DoençasAutoimunes #DoençasDoSangue

Post attachment
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·7 Nov 2024

I shared with @correio an exciting advance for Hodgkin lymphoma patients: a treatment combining immunotherapy and low-dose chemo. Results show 92% of patients had no disease progression. Nivolumab boosts the immune system and lowers long-term side effects. correiobraziliense.com.br/ci… #Oncology

Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·31 Oct 2024

Imagine um tratamento capaz de transformar o cenário das doenças autoimunes graves e refratárias. É justamente essa inovação que será tema do Summit CAR-T Cell, organizado pelo Núcleo de Doenças Autoimunes da BP – A Beneficência Portuguesa de São Paulo! Nesta edição especial, teremos a honra de receber o Dr. Fabian Muller, referência mundial em CAR-T pela Universidade de Erlangen, Alemanha. Ele apresentará a abordagem revolucionária “CD19 CAR T-Cell Therapy in Autoimmune Disease” e discutirá como essa tecnologia, que já transformou o tratamento de cânceres hematológicos, está sendo empregada com sucesso em casos complexos como lúpus eritematoso sistêmico, esclerodermia e outras doenças autoimunes. Estou ansioso para mediar esse encontro, que contará também com a presença do Dr. Diego Villa Clé, Coordenador do Núcleo de Terapias Avançadas (NUTERA) do Hemocentro de Ribeirão Preto da USP. 🚨 Está cada dia mais próximo! Anote na agenda: 📅 Data: 12 de novembro ⏰ Horário: 13h00 às 14h30 📍 Local: Auditório BP Mirante Não perca! #Hematologia #Hematologista #BP #OncoHematologia #ABeneficênciaPortuguesaDeSãoPaulo #DoençasAutoimunes #DoençasDoSangue

Post attachment
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·30 Oct 2024

O HEMO 2024 foi um evento incrível! Foram quatro dias intensos, onde especialistas do Brasil e do exterior, #Hematologistas e profissionais da saúde se encontraram para discutir as inovações e desafios das doenças onco-hematológicas. Além disso, tivemos a Sessão Conjunta entre A Associação Brasileira de Hematologia Hemoterapia (ABHH) e a Sociedade de Onco-Hematologia Americana (SOHO) com discussões interessantíssimas e uma troca muito rica com a presença de grandes experts da área. Em breve, vou compartilhar as principais novidades e insights que trouxe desse encontro. #HEMO2024 #Hematologista #ABHH #SOHO

0:30
Phillip Scheinberg avatar
Phillip Scheinberg@scheinbp·22 Oct 2024

We were honored to have Dr. @Ramikomrokji at today’s Heme Noon Conference at my Hospital. His insightful talk sparked great discussions and valuable exchanges. Thank you, Rami, for your fantastic contribution, it was a pleasure having you with us!

Post attachment